Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

Published:2013-09-12 Issue:12 Volume:88 Page:1024-1029
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Falchi Lorenzo¹,Kantarjian Hagop M.¹,Wang Xuemei²,Verma Dushyant¹,Quintás‐Cardama Alfonso¹,O'Brien Susan¹,Jabbour Elias J.¹,Ravandi‐Kashani Farhad¹,Borthakur Gautam¹,Garcia‐Manero Guillermo¹,Verstovsek Srdan¹,Burger Jan A.¹,Luthra Raja³,Cortes Jorge E.¹

Affiliation:

1. Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston Texas

2. Department of BiostatisticsThe University of Texas MD Anderson Cancer CenterHouston Texas

3. Department of HematopathologyThe University of Texas MD Anderson Cancer CenterHouston Texas

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.23560

Reference29 articles.

1. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

2. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

3. High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses

4. Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study

5. Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results;Leukemia;2024-05-16

2. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results;Leukemia;2023-03-22

3. Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia;Cancers;2021-11-20

4. Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?;Cancers;2021-08-19

5. Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?;International Journal of Molecular Sciences;2021-06-30